Reducing Antimicrobial Overuse Through Targeted Therapy for Patients With Community-Acquired Pneumonia
Key facts
- Who runs it
- The Cleveland Clinic
- Where
- Akron, Avon, Cleveland, Euclid, Fairview Park, Garfield Heights, Mayfield Heights, Medina, Vero Beach, Warrensville Heights, and Weston, United StatesSee the 12 sites
- Trial code
- Status
- Completed
- People taking part
- 28,580 people enrolled
- Started
- 1 Nov 2022
- Ended
- 30 Jun 2026
- Type of study
- Interventional, 4 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Rapid Diagnostic Testing
- Pharmacist-led de-escalation
- Record updated
- 1 July 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Men or women greater than or equal to 18 years of age
- Admitted to a participating (i.e. enrolled and randomized) hospital
- Admitting diagnosis of pneumonia
Who cannot take part
- Patients not eligible for empiric therapy due to a known pathogen (any positive blood or respiratory cultures in the 72 hours prior to admission)
- Admission to intensive care unit within 24 hours of hospital admission
- Comfort care measures only
- Cystic fibrosis
- Discharged from an acute care hospital in the past week
Where in United States
- Akron General HospitalAkron, United States
- Avon HospitalAvon, United States
- Cleveland Clinic - Main CampusCleveland, United States
- Lutheran HospitalCleveland, United States
- Euclid HospitalEuclid, United States
- Fairview HospitalFairview Park, United States
- Marymount HospitalGarfield Heights, United States
- Hillcrest HospitalMayfield Heights, United States
- Medina HospitalMedina, United States
- Indian River HospitalVero Beach, United States
- South Pointe HospitalWarrensville Heights, United States
- Weston Hospital - Cleveland Clinic FloridaWeston, United States
About the trial
What the trial wants to find out
The purpose of this study is to reduce the exposure of broad-spectrum antimicrobials by optimizing the rapid detection of CAP pathogens and improving rates of de-escalation following negative cultures. To accomplish this, we will perform a 3-year, pragmatic, multicenter 2 X 2 factorial cluster randomized controlled trial with four arms: a) rapid diagnostic testing b) pharmacist-led de-escalation c) rapid diagnostic testing + pharmacist-led de-escalation and d) usual care
The 4 groups in the trial
- Rapid diagnostic testing (RDT)Existing treatment, for comparison
Rapid diagnostic testing: Eligible patients at hospitals randomized to this arm will undergo testing for viral pathogens (from November-April) and pneumococcal UAT and procalcitonin testing. If the patient is not being admitted to the ICU, and the patient has an admitting diagnosis of pneumonia, the form will append orders for viral testing, UAT and procalcitonin testing to providers in hospitals randomized to receive it.
Treatment: Rapid Diagnostic Testing
- Pharmacist-led de-escalationExisting treatment, for comparison
Pharmacist-led de-escalation: Another CDSS algorithm will identify CAP patients who meet study criteria and have negative culture results for \> 48 hours and generate a list for the clinical pharmacist, who will be a member of the study team. The alerts will be audited by the pharmacist daily on weekdays at a centralized location. The pharmacist will attempt to determine whether each patient is clinically stable. The validated measures of clinical stability in patients with CAP are a) resolved vital sign abnormalities b) normal mental status c) ability to eat. If the patient appears stable, the pharmacist will communicate their recommendations for de-escalation to the clinical providers via a phone call or page.
- Rapid diagnostic testing (RDT) and Pharmacist-led de-escalationExisting treatment, for comparison
Rapid diagnostic testing: Eligible patients at hospitals randomized to this arm will undergo testing for viral pathogens (from November-April) and pneumococcal UAT and procalcitonin testing. If the patient is not being admitted to the ICU, and the patient has an admitting diagnosis of pneumonia, the form will append orders for viral, UAT and procalcitonin testing to providers in hospitals randomized to receive it. Pharmacist-led de-escalation: Another CDSS algorithm will identify CAP patients who meet study criteria and have negative culture results for \>48-hours and generate a list for the clinical pharmacist, who will be a member of the study team. The alerts will be audited by the pharmacist daily on weekdays at a centralized location. The pharmacist will attempt to determine whether each patient is clinically stable. If the patient appears stable, the pharmacist will communicate their recommendations for de-escalation to the clinical providers via a phone call or page.
Treatment: Rapid Diagnostic Testing and Pharmacist-led de-escalation
- Usual care (no intervention)No study treatment, for comparison
Usual care
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Publications
- Record updated
- 1 July 2026